U.S. Pharmacist

01/22/2026

The End of "Trial and Error"

We’ve all seen patients struggle through the "trial and error" phase of finding the right medication. But what if their DNA could give us the answer first?
🧬 Pharmacogenomics (PGx) is shifting the paradigm from "one size fits all" to personalized precision. From mental health meds to blood thinners, testing can predict who will respond—and who might suffer an adverse reaction.
Read how this technology is becoming a standard part of medication selection.
🔗 https://ow.ly/Of6f50Y0Wby

01/21/2026

The January 2026 issue of U.S. Pharmacist is here!

We are kicking off the new year with a focus on Neurology and Biologics. From breakthrough therapies in migraine prevention to the complexities of managing Huntington’s Disease, this issue provides the critical updates you need for complex patient care.

Inside this month:
🧠 Neurology: Biologics in Multiple Sclerosis & breakthroughs in Migraine prevention.
🏥 Geriatrics: Optimizing dementia care in the hospital setting.
⚠️ Oncology: The rising urgency of early-onset Colorectal Cancer detection.
📉 Public Health: New data on rising cognitive disability among U.S. adults.

Read the full digital edition for free! 📖

🔗 https://www.uspharmacist.com/issue/january-2026

01/19/2026

"Of all the forms of inequality, injustice in health is the most shocking and the most inhuman."

Today, we honor the life and legacy of Dr. Martin Luther King Jr. His words remind us that the work of equality is not limited to courtrooms or voting booths—it extends to our clinics, our counters, and our communities.

For 50 years, U.S. Pharmacist has supported the pharmacy profession as you care for patients from all walks of life. Today, we reflect on the vital role pharmacists play in bridging gaps in care, addressing health disparities, and ensuring that quality healthcare is accessible to everyone.

01/14/2026

To cap or not to cap? � When treating GI cancers in patients with obesity, the "fear of toxicity" often leads to dose reductions. But is this practice hurting survival rates?

A new review in U.S. Pharmacist examines the altered pharmacokinetics in obesity—from changes in CYP enzyme activity to volume of distribution (Vd) differences between lipophilic and hydrophilic agents.

Key Takeaway: Despite the physiological changes, ASCO guidelines continue to recommend full weight-based dosing for most cytotoxic agents. The data suggests that underdosing may be a greater risk to patient outcomes than the potential for toxicity.

Read the full review on PK/PD changes and the "Obesity Paradox" in immunotherapy below. �

https://www.uspharmacist.com/article/how-obesity-affects-drugs-used-to-treat-gi-cancers

01/12/2026

Happy National Pharmacist Day to the experts who can read doctors' handwriting better than anyone else! 😉✍️

In all seriousness, thank you for being the guardians of medication safety and the trusted faces we turn to for advice. You make a difference in so many lives, today and every day.

12/09/2025

Hepatitis B Vaccine 💉

Hepatitis B vaccination is drawing renewed attention after a CDC advisory panel on Friday voted to no longer recommend the shot for all newborns. The call has drawn strong reaction from medical groups, who – citing recent shifts in the panel – are urging doctors and parents to rely on alternative guidance grounded in longstanding evidence. The decision isn't just about newborns – it raises broader questions about protection across all ages and why adult immunity still matters for public health. https://wb.md/4908XmE

12/05/2025

Ready for the biggest week in pharmacy? 💊✨

The U.S. Pharmacist team is excited to be exhibiting at the ASHP Midyear Clinical Meeting in Las Vegas. Make sure to add Booth 954 to your exhibit hall route!

✅ Grab our latest print issues
✅ Meet the team behind the journal
✅ Share your feedback on our content
✅ Sign up for our emails

Safe travels to everyone flying in—we'll see you at Booth 954!

12/04/2025

Test and Treat at Pharmacy could be used for more illnesses

Pharmacists could comfortably and accurately perform high-quality rapid testing for respiratory illness and, at the same time, provide quick and effective treatment options for patients, according to a study conducted by the APhA Foundation. https://ow.ly/jzqR50Xyl94

12/02/2025

Did you know that 80% of individuals with Type 2 diabetes are obese at diagnosis or have a history of obesity? 📉

The convergence of these two pandemics—coined "Diabesity"—presents a unique challenge for pharmacists. From medication selection to lifestyle counseling, your role is more vital than ever.

Get the facts in our latest article from the journal you’ve trusted for 50 years: https://www.uspharmacist.com/article/confronting-the-diabesity-epidemic

Published November 14, 2025 DIABETES Confronting the Diabesity Epidemic Manouchehr Saljoughian, PharmD, PhDU.S. PharmacistNewark, New Jersey US Pharm. 2025;50(11):23-25.In recent years, the prevalence of obesity has rapidly increased, accompanied by an exponential rise in the incidence of type 2 dia...

11/17/2025

Improve Adherence with Patient Teaching Aids

Effective patient counseling is key. U.S. Pharmacist has new, easy-to-use patient teaching aids to help you and your patients. Access the latest resources for diabetes, asthma, and more.

💊Find counseling aids for your patients here: https://www.uspharmacist.com/teaching-aids

10/29/2025

New Drugs of 2025: Your Essential Practice Update is Here! 💊

The October issue of U.S. Pharmacist has published its annual New Drug Review 2025, providing in-depth profiles on the latest FDA-approved New Molecular Entities (NMEs) you need to know.

Our expert review by Jack DeRuiter, PhD and Hill Crest Professor, Pamela L. Holston,, RPh, BS, BA, and Adam Harnden, PharmD, BCPS, covers the clinical data, pharmacology, precautions, and dosing for game-changing therapies, including:
- Acoltremon (Tryptyr): A first-in-class treatment for Dry Eye Disease (DED), offering a new mechanism of action for millions of patients struggling with this common condition.
- Suzetrigine (Journavx): A novel, non-opioid oral analgesic approved for moderate-to-severe acute pain, providing an alternative to traditional pain management protocols.
- Gepotidacin (Blujepa): A first-in-class oral antibiotic for uncomplicated urinary tract infections (uUTIs), crucial for tackling the rise of drug-resistant bacteria.
- Vanzacaftor/Tezacaftor/Deutivacaftor (Alyftrek): A new triple combination therapy for Cystic Fibrosis (CF).

Staying current on NMEs is vital for patient counseling, drug utilization review, and medication safety.

Click below to read the full review and earn your Continuing Education (CE) credits:

[Link to: https://www.uspharmacist.com/article/new-drug-review-2025]

10/23/2025

Happy National Pharmacy Week! 💊

Celebrating all the incredible pharmacists and their unwavering dedication to our health and well-being. Thank you for being our healthcare heroes!

Like & Follow U.S. Pharmacist